<p>Shandong Xinhua Pharmaceutical Company Limited has decided to terminate its previously announced equity acquisition intention agreement with NovoSana (Europe) B.V. The company cited that, despite initial friendly negotiations, the parties were unable to reach a consensus on the terms and conditions of a formal agreement. As a result, the project will not proceed. The company stated that this decision will not affect its current operations or development. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shandong Xinhua Pharmaceutical Company Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260206-12017960), on February 06, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)</p>

000756

Shandong Xinhua Pharmaceutical Ends Equity Acquisition Talks with NovoSana